Immunotherapy before surgery for dMMR/MSI-H stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether giving immunotherapy before surgery can help people with a specific type of stomach cancer (dMMR/MSI-H) that can be removed. It aims to see how well the immune system responds and if the tumor shrinks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 85 years old.
- You have a type of stomach or gastroesophageal junction cancer (Siewert types II or III) that is adenocarcinoma.
- Your tumor has a specific genetic marker called dMMR or MSI-H.
- Your tumor is at a stage where it can be removed with surgery, and you will get treatment before surgery.
- You are willing to receive immunotherapy (drugs that help your immune system fight cancer).
- You have not had any other cancer treatment for this stomach cancer yet.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug (adebrelimab) combined with chemotherapy or another drug (SHR-8068) for a specific type of advanced stomach cancer that has a genetic marker called dMMR or MSI-H. The goal is to see if these combinations can make the tumor shrink enough to be removed with surgery.
This trial tests whether patients with advanced gastric cancer (a specific type called dMMR/MSI-H) can be treated without surgery after receiving immunotherapy and chemotherapy. The goal is to see if this approach can control the cancer while avoiding the risks of surgery.
This trial tests combining an immunotherapy drug (sintilimab) with low-dose radiation before surgery for stomach cancer that has a specific genetic marker (dMMR/MSI-H). The goal is to see if this combination can shrink the tumor and improve outcomes without needing strong chemo.
This trial tests two immunotherapy drugs given before surgery for locally advanced gastric cancer that has a specific genetic marker (MSI-H or dMMR). The goal is to shrink the tumor and improve outcomes before removing it surgically.
This trial tests whether using immune checkpoint inhibitors alone (like checkpoint blockade drugs) can help people with certain gastric or colon cancers avoid surgery. It's for patients whose tumors have a specific genetic feature called dMMR/MSI-H and haven't spread to other parts of the body.
This trial tests whether giving immunotherapy before surgery, with or without radiation, can help shrink locally advanced colorectal cancer that has a specific genetic marker (MSI-H or dMMR). It aims to improve outcomes for patients who have not yet had any treatment.
Hear when a new Gastric / Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.